Commonwealth Equity Services’s Titan Pharmaceuticals TTNP Stock Holding History

Commonwealth Equity Services’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-74	Closed	-$10K	–	3007
2020 Q1	$10K	Buy	+74	New	+$11.6K	﹤0.01%	2789
2019 Q1	–	Sell	-3	Closed	-$2K	–	2784
2018 Q4	$2K	Sell	3 -1	-25%	-$1.12K	﹤0.01%	2674
2018 Q3	$2K	Buy	+4	New	+$10.9K	﹤0.01%	2786

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CWM

Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Commonwealth Equity Services's TTNP Position: Q2 2020 in Review

Commonwealth Equity Services sold out of Titan Pharmaceuticals (TTNP) in Q2 2020, closing a stake of 74 shares — an estimated $10K sold.

Commonwealth Equity Services first reported a position in TTNP in Q3 2018 and held it in 3 quarters. The position peaked at $10K in Q1 2020. 23 funds tracked by Wall St. Rank hold TTNP as of Q2 2020.

Commonwealth Equity Services reported no remaining Titan Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Commonwealth Equity Services sold 74 Titan Pharmaceuticals shares in Q2 2020, an estimated $10K.
Commonwealth Equity Services first reported a position in Titan Pharmaceuticals in Q3 2018 and held it in 3 quarters.
Commonwealth Equity Services's Titan Pharmaceuticals position peaked at $10K in Q1 2020.
23 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2020.

Based on Commonwealth Equity Services's 13F filing for Q2 2020, filed 12 Aug 2020.